相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases
Carla Isabelly Rodrigues-Fernandes et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2021)
Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution
Maria Queralt Salas et al.
BIOMARKERS (2020)
Soluble CD30, the Immune Response, and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-Analysis
Mohammad Mirzakhani et al.
FRONTIERS IN IMMUNOLOGY (2020)
High-grade B-cell lymphoma: how to diagnose and treat
Mattia Novo et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Clinicopathological analysis of oral diffuse large B-cell lymphoma, NOS: A systematic review
Carla Isabelly Rodrigues-Fernandes et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Yang Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management
Jorge J. Castillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma
Qi-Xing Gong et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Nancy L. Bartlett et al.
LEUKEMIA & LYMPHOMA (2017)
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
John Matthew R. Pierce et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
CD30 Expression and Prognostic Significance in R-EPOCH-Treated Patients with Diffuse Large B-Cell Lymphoma
Jie Xu et al.
HUMAN PATHOLOGY (2017)
Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects
Naoko Tsuyama et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2017)
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Lesley J. Scott
DRUGS (2017)
CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma
Xuan J. Wang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma
Morton Coleman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis
Chen-Ge Song et al.
PLOS ONE (2015)
The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma
Xiaoxiao Hao et al.
PLOS ONE (2015)
Genetic and Immunohistochemical Characterization of Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma
S. Al-Humood et al.
ACTA HAEMATOLOGICA (2014)
CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia
Graham W. Slack et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Prevalence and Clinical Implications of Epstein-Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
Chi Young Ok et al.
CLINICAL CANCER RESEARCH (2014)
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu et al.
BLOOD (2013)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
分享论文
